Question

A 47-year-old man with NSTEMI and new HFrEF (EF 35%) is discharged on ARNI, beta-blocker, and high-intensity statin. Which additional drug class provides mortality benefit and should be added barring contraindication?

Accepted Answer

Mineralocorticoid receptor antagonist

Answer

Loop diuretic

Answer

Ivabradine

Answer

Ranolazine

Answer

Omega-3 fatty acids

Practice question

A 47-year-old man with NSTEMI and new HFrEF (EF 35%) is discharged on ARNI, beta-blocker, and high-intensity statin. Which additional drug class provides mortality benefit and should be added barring contraindication?